HRP20080493T3 - Supstituirani kinolinski derivati kao mitotski inhibitori kinezina - Google Patents

Supstituirani kinolinski derivati kao mitotski inhibitori kinezina

Info

Publication number
HRP20080493T3
HRP20080493T3 HR20080493T HRP20080493T HRP20080493T3 HR P20080493 T3 HRP20080493 T3 HR P20080493T3 HR 20080493 T HR20080493 T HR 20080493T HR P20080493 T HRP20080493 T HR P20080493T HR P20080493 T3 HRP20080493 T3 HR P20080493T3
Authority
HR
Croatia
Prior art keywords
group
alkyl
hydroxy
halogen
alkylene
Prior art date
Application number
HR20080493T
Other languages
English (en)
Croatian (hr)
Inventor
Wang W.
Constantine R.
Lagniton L.
Bair K.
Original Assignee
Novartis Vaccines & Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostics filed Critical Novartis Vaccines & Diagnostics
Publication of HRP20080493T3 publication Critical patent/HRP20080493T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20080493T 2004-05-21 2005-05-19 Supstituirani kinolinski derivati kao mitotski inhibitori kinezina HRP20080493T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57312004P 2004-05-21 2004-05-21
PCT/US2005/017961 WO2005113507A1 (en) 2004-05-21 2005-05-19 Substituted quinoline derivatives as mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
HRP20080493T3 true HRP20080493T3 (hr) 2009-02-28

Family

ID=34970815

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080493T HRP20080493T3 (hr) 2004-05-21 2005-05-19 Supstituirani kinolinski derivati kao mitotski inhibitori kinezina

Country Status (19)

Country Link
US (2) US7452996B2 (enExample)
EP (1) EP1753723B1 (enExample)
JP (1) JP2008502721A (enExample)
CN (1) CN1956960A (enExample)
AT (1) ATE404536T1 (enExample)
AU (1) AU2005245492A1 (enExample)
BR (1) BRPI0511433A (enExample)
CA (1) CA2564215A1 (enExample)
DE (1) DE602005008953D1 (enExample)
DK (1) DK1753723T3 (enExample)
ES (1) ES2311992T3 (enExample)
HR (1) HRP20080493T3 (enExample)
MX (1) MXPA06011958A (enExample)
PL (1) PL1753723T3 (enExample)
PT (1) PT1753723E (enExample)
RS (1) RS50670B (enExample)
RU (1) RU2385867C2 (enExample)
SI (1) SI1753723T1 (enExample)
WO (1) WO2005113507A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511433A (pt) * 2004-05-21 2007-12-11 Chiron Corp derivados de quinolina substituìda como inibidores de cinesina mitótica
AU2005273705B8 (en) 2004-08-18 2010-01-28 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP3095456A1 (en) * 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
CA2668661A1 (en) * 2006-11-13 2008-05-29 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors
MX2009007260A (es) * 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
US8748626B2 (en) * 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
AU2011239977B2 (en) * 2010-04-15 2014-11-27 Novartis Ag Triazole compounds as KSP inhibitors
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
NZ631362A (en) * 2012-08-13 2016-09-30 Array Biopharma Inc Arry-520 for use in treating cancer in a patient with low aag
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
RU2728932C2 (ru) * 2015-08-19 2020-08-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения рака желчевыводящих путей
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
KR100883184B1 (ko) 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
EP1351671A1 (en) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
EP1360180A1 (en) 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
EP1481077B1 (en) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1551812B1 (en) 2001-12-06 2009-03-04 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
PL211300B1 (pl) 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
PL374190A1 (en) 2002-06-14 2005-10-03 Merck & Co, Inc. Mitotic kinesin inhibitors
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン結合部位
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
BRPI0511433A (pt) * 2004-05-21 2007-12-11 Chiron Corp derivados de quinolina substituìda como inibidores de cinesina mitótica

Also Published As

Publication number Publication date
CN1956960A (zh) 2007-05-02
PL1753723T3 (pl) 2009-01-30
WO2005113507A1 (en) 2005-12-01
JP2008502721A (ja) 2008-01-31
ATE404536T1 (de) 2008-08-15
US20090028858A1 (en) 2009-01-29
BRPI0511433A (pt) 2007-12-11
EP1753723B1 (en) 2008-08-13
DK1753723T3 (da) 2008-10-20
RS50670B (sr) 2010-06-30
CA2564215A1 (en) 2005-12-01
AU2005245492A1 (en) 2005-12-01
US20050261337A1 (en) 2005-11-24
RU2385867C2 (ru) 2010-04-10
ES2311992T3 (es) 2009-02-16
SI1753723T1 (sl) 2009-04-30
PT1753723E (pt) 2008-11-19
EP1753723A1 (en) 2007-02-21
MXPA06011958A (es) 2006-12-15
DE602005008953D1 (de) 2008-09-25
US7452996B2 (en) 2008-11-18
RU2006145336A (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
HRP20080493T3 (hr) Supstituirani kinolinski derivati kao mitotski inhibitori kinezina
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
HRP20020175B1 (hr) N-heterociklički derivati kao inhibitori nos
MY158055A (en) Tetrahydroquinoline derivatives and a process for preparing the same.
HRP20070510T3 (hr) Derivati benzimidazola i njihova upotreba kao antagonista ii receptora
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
EA201170196A1 (ru) Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов
RU2013116924A (ru) N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз
ES2570756T3 (es) Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
ATE556058T1 (de) 1-(2h)-isochinolonderivat
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
MY139887A (en) Tetrahydronaphthyridine derivatives and a process for preparing the same.
WO2008087611A3 (en) Pyrrolidine- and piperidine- bis-amide derivatives
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
SE0201937D0 (sv) Therapeutic agents
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
AR049346A1 (es) 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas